v3.26.1
Nature of Operations, Basis of Presentation, and Liquidity (Details)
3 Months Ended
Apr. 29, 2025
$ / shares
Oct. 01, 2024
USD ($)
Jan. 18, 2022
USD ($)
Mar. 31, 2026
USD ($)
D
$ / shares
Dec. 31, 2025
USD ($)
$ / shares
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Nature of Operations, Basis of Presentation, and Liquidity              
Reverse stock split ratio 0.04            
Common stock, par value (in dollars per share) | $ / shares $ 0.0001     $ 0.0001 $ 0.0001    
Cash and cash equivalents       $ 4,352,450 $ 5,136,722    
Working capital       (1,800,000)      
Accumulated deficit       $ 112,281,812 $ 111,294,776    
Regulatory approvals in metuchen affiliates | D       30      
ABC Assets              
Nature of Operations, Basis of Presentation, and Liquidity              
Liquidation fees agreed to pay           $ 60,000  
Liquidation cash fee payable           9.00%  
Notes payable              
Nature of Operations, Basis of Presentation, and Liquidity              
Principal amount of notes payable     $ 10,201,758        
Payment due pursuant to the note and security agreement   $ 500,000          
Principal balance             $ 7,574,824
Foreclosed collateral       $ 2,000,000      
Vivus, Inc              
Nature of Operations, Basis of Presentation, and Liquidity              
Purchase of obligation     12,400,000        
Purchase commitments     4,250,000        
Vivus, Inc | Settlement Agreement              
Nature of Operations, Basis of Presentation, and Liquidity              
Inventory amount retained - API     7,300,000        
Payment made for purchase order     $ 1,542,904        
Percentage of stendra tablets released     50        
Vivus, Inc | Settlement Agreement | Promissory Note              
Nature of Operations, Basis of Presentation, and Liquidity              
Prepayment amount     $ 900,000